Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Rating Reaffirmed by HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 268.42% from the stock’s current price. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings at ($0.30) EPS, Q3 2023 earnings at ($0.36) EPS and Q4 2023 earnings at ($0.42) EPS.

Armata Pharmaceuticals Price Performance

NYSEAMERICAN ARMP opened at $1.90 on Friday. Armata Pharmaceuticals has a 52-week low of $0.83 and a 52-week high of $5.79. The company has a market cap of $68.69 million, a P/E ratio of -1.84 and a beta of 1.27.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several hedge funds have recently made changes to their positions in ARMP. Vanguard Group Inc. grew its stake in shares of Armata Pharmaceuticals by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company’s stock worth $1,335,000 after acquiring an additional 10,400 shares in the last quarter. Northern Trust Corp bought a new position in shares of Armata Pharmaceuticals during the 1st quarter worth approximately $95,000. HRT Financial LP bought a new position in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $52,000. Renaissance Technologies LLC grew its stake in shares of Armata Pharmaceuticals by 5.6% during the 4th quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock worth $91,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $25,000. 3.76% of the stock is owned by institutional investors.

About Armata Pharmaceuticals

(Get Rating)

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.